

Dr. rer. nat. habil. Andreas Martin Kaufmann

Charité-Universitätsmedizin Berlin
Campus Virchow Klinikum
Laboratory „Gynecologic Tumor Immunology“
Südring 11 (intern)
Augustenburgerplatz 1
13353 Berlin, Germany
Tel. : +49-30-450-516499
e.mail: andreas.kaufmann@charite.de
https://frauenklinik.charite.de/forschung/ags/hpv_labor/
ORCID: 0000-0001-7732-3009



Curriculum Vitae

Gender	male
05. March 1961	Born in Weinheim an der Bergstraße, Baden-Württemberg, Germany
privat address	Lörracherstrasse 2a, 12247 Berlin
Education	
1980 - 1987	Studies of Biology at University of Heidelberg, Germany.
1986 - 1987	Diploma thesis at the Institute for Experimental Pathology Deutsches Krebsforschungszentrum (DKFZ), Heidelberg
1987	Diploma in Biology, Ruprecht-Karls-University, Heidelberg
1987 - 1992	Doctoral thesis at the Institute for Immunology und Genetics, DKFZ
1992	PhD in Biology, Ruprecht-Karls-University, Heidelberg
1992 - 1994	post-doc I: Institute for Immunology und Genetics, DKFZ
1994 - 1997	post-doc II: Department for Obstetrics and Gynecology, Division of Research, Loyola University Medical Center, Chicago, IL, USA
1997 - 2004	Senior Scientist, Clinical Research Group „Gynecologic Molecular Biology“ Frauenklinik, Friedrich-Schiller-University, Jena
12/2004	Habilitation, Friedrich-Schiller-University, Jena
since 9/2004	Charité-Universitätsmedizin Berlin, Campus CBF/CCM/CKV, Research, Clinic for Gynecology, Laboratory „Gynecologic Tumor Immunology“
11/2020	Appointed extraordinary professor at the <i>Pan African Cancer Research Institute</i> , University of Pretoria, South Africa
Objectives	Translational research from biological basic science to medical application. Development of therapeutic vaccines for cervical cancer. Immunology of prophylactic HPV vaccines. HPV genotyping for advanced screening and epidemiological studies. Participation in collaborative clinical research projects (local, national, international, especially LMIC).

Opinion leadership

Member of German Medical Guideline Conferences

- HPV Impfung (HPV vaccination): S3 guideline “Prävention HPV-assoziiertes Neoplasien” (Prevention of HPV-associated neoplasia), AWMF Nr. 082-002 (valid until 31.12.2018), Member since 2007
- Zervixkarzinomprävention (Cervical Cancer Prevention): S3 guideline “Prävention des Zervixkarzinoms” (Prevention of cervical cancer), Member since 2013

Member of Working groups

- Member of the Study Group Colposcopy (Germany) (Studiengruppe Kolposkopie e.V.)
- Member of HPV Management Forum (Working Group of Paul-Ehrlich Society)
- Member of the policy board of the International Papillomavirus Society
- Member of the board of directors of the International Papillomavirus Society (rotated out)

Berlin, September 28th 2022